Dyslipidaemia management & statin therapy
lipids · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Assessment and treatment of elevated LDL and other lipids to reduce atherosclerotic cardiovascular risk, using risk stratification and statin-based therapy. Secondary and familial causes should be excluded first.
Red flags
- Triglycerides >11 mmol/L (pancreatitis risk)
- Features of familial hypercholesterolaemia
- Muscle pain with marked CK rise (rhabdomyolysis)
- New cardiovascular event on treatment
- Unexplained transaminase elevation >3x upper limit
Assessment
Differential diagnosis
- Familial hypercholesterolaemia
- Secondary dyslipidaemia (hypothyroidism, diabetes, nephrotic, alcohol)
- Familial combined hyperlipidaemia
- Severe hypertriglyceridaemia
- Metabolic syndrome
Investigations
- Lipid profile (total, LDL, HDL, triglycerides, non-HDL)
- Cardiovascular risk calculation (e.g. QRISK3)
- TSH, HbA1c, renal and liver function
- Lipoprotein(a) once in a lifetime
- Baseline creatine kinase if muscle symptoms/risk
Management
- Exclude and treat secondary causes before committing to lifelong therapy
- Stratify risk: established cardiovascular disease, diabetes, CKD, FH, or calculated risk
- Advise diet, weight, exercise, smoking cessation and alcohol moderation
- Offer high-intensity statin for secondary prevention and high-risk primary prevention
- Set goals: >=40% non-HDL reduction (primary) or lower absolute LDL targets in high-risk/secondary prevention
- Check response and adherence at 2-3 months; uptitrate as needed
- Add ezetimibe then PCSK9 inhibitor/inclisiran/bempedoic acid if targets unmet
- Manage significant hypertriglyceridaemia (fibrate/icosapent ethyl) once LDL controlled
- Monitor liver enzymes and manage statin intolerance with rechallenge/alternatives
- Review cardiovascular risk periodically
Drugs & doses
Atorvastatin 20-80 mg or rosuvastatin 10-40 mg PO once daily
Ezetimibe 10 mg PO once daily
PCSK9 inhibitor (alirocumab/evolocumab) SC or inclisiran SC twice yearly
Icosapent ethyl 2 g PO twice daily for residual hypertriglyceridaemia
Fenofibrate 145 mg PO once daily for marked hypertriglyceridaemia
Disposition
Manage in primary care with risk-based follow-up; refer to lipid clinic for suspected FH, statin intolerance, or targets unmet on combination therapy.
Complications & pitfalls
- Atherosclerotic cardiovascular disease
- Acute pancreatitis (severe hypertriglyceridaemia)
- Statin-associated muscle symptoms/rhabdomyolysis
- Undertreatment of high-risk patients
Exam pearls
- Lower LDL is better in high-risk patients; combine agents to reach target
- Most statin muscle symptoms are not true myopathy; rechallenge or switch rather than abandon
- Check lipoprotein(a) once as an independent residual risk marker
- Very high triglycerides threaten the pancreas and need triglyceride-focused therapy first
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.